Core Framework & Diagram The Birth of CAR-T (From Failure to Breakthrough)
July 24, 20261 Min Read How Did HIV Change Immunology?
July 24, 2026Retrofitting T cells into precision-guided weapons
—— This idea took thirty years to go from science fiction to reality.
I. An Israeli immunologist's original idea
In 1989, Zelig Eshhar at the Weizmann Institute of Science in Israel published a paper describing an experimental concept. Understanding this concept requires first understanding a fundamental limitation of T cell target recognition. T cells recognize targets through their T cell receptor (TCR), but this process requires MHC molecule assistance — the target cell must present internal protein fragments (antigen peptides) on MHC-I molecules for T cells to 'see' them. This mechanism is extremely precise, but has two fatal weaknesses: first, tumor cells can go invisible by downregulating MHC-I; second, T cells can only recognize things presented as intracellular antigen fragments, unable to directly recognize cell surface proteins. Antibodies are completely different — antibodies need no MHC and can directly recognize any protein on a cell surface. Eshhar's idea: could the antigen-binding portion of an antibody (single-chain variable fragment, scFv) be connected with the T cell receptor's signal transduction structure (CD3ζ chain) to create a 'chimeric' artificial receptor — giving T cells both antibodies' direct recognition ability and T cells' own killing capacity? This artificial receptor became the CAR (Chimeric Antigen Receptor). The first batch of experimental results was disappointing. First-generation CAR could indeed recognize and kill cells expressing the target protein in vitro, but once the modified T cells were injected into animals, they quickly died, unable to maintain sufficient numbers and activity — tumor control was nearly zero.
2. Ten years of stagnation: missing one critical 'survival signal'
First-generation CAR failure's cause was gradually elucidated: T cells' persistent survival and effective function require not just 'an activation signal' (first signal provided by CD3ζ chain) but also a 'live on signal' — co-stimulatory signal (second signal). In normal T cell activation, this second signal is provided by co-stimulatory receptor (like CD28) binding to its ligand (B7 molecule). Without the second signal, T cells don't truly fully activate, entering a state called 'anergy,' then dying. This was also why first-generation CAR-modified T cells couldn't persist in vivo — they only had the first signal, no second signal. Around 2002, Carl June at University of Pennsylvania, Michel Sadelain at Memorial Sloan Kettering Cancer Center, and other teams almost simultaneously published second-generation CAR data. After adding CD28 or 4-1BB (CD137) co-stimulatory domains, modified T cells in vivo could not only kill tumors but massively expand (peak numbers could exceed infusion amounts by over 1,000 times), survive long-term (in some patients, CAR-T cells were still detectable years after infusion), and after eliminating tumors form memory cells providing durable protection.
CD28 and 4-1BB co-stimulatory domain choices affect CAR-T's functional characteristics: CD28 co-stimulation produces faster initial expansion, suited for rapid tumor burden control; 4-1BB co-stimulation produces more durable memory-type CAR-T cells, suited for scenarios requiring long-term surveillance. Currently approved two main products — Kymriah (CD19, 4-1BB co-stimulation) and Yescarta (CD19, CD28 co-stimulation) — represent these two design philosophies.
3. Why CD19 was chosen as the target
Second-generation CAR proved technical feasibility, but still needed to select an appropriate target. Target selection is key to CAR-T therapy success or failure: ideal targets should be uniformly highly expressed on tumor cell surfaces, while not expressed in normal tissue (or only expressed in tissue that can be sacrificed). June's team selected CD19 — a protein highly expressed on B cell (including B cell leukemia and lymphoma cells) surfaces. CD19's advantages: almost all B cell leukemia and lymphoma cells express it, expression density is high and uniform, not easily lost. CD19's one potential problem: normal B cells also express this protein, so CD19 CAR-T while attacking tumors also eliminates normal B cells, causing persistent B cell aplasia. But the team considered this an 'acceptable on-target toxicity' — patients losing B cells can compensate for antibody deficiency through regular immunoglobulin (IVIG) infusions, and this side effect is simultaneously indirect evidence of CAR-T persistently active in the body.
4. Emily Whitehead: a child who changed history
In 2012, the University of Pennsylvania and Children's Hospital of Philadelphia team faced a six-year-old girl: Emily Whitehead. She had acute lymphoblastic leukemia (ALL), relapsed after two standard chemotherapy courses, and deteriorated again during bone marrow transplant preparation. She had exhausted all standard treatment options. Her tumor cells expressed CD19 — she met CAR-T clinical trial entry criteria, becoming one of the youngest patients to receive CD19 CAR-T treatment. The days after infusion were the entire medical team's most agonizing time. Emily developed severe Cytokine Release Syndrome (CRS) — high fever persisting for days, hypotension, multi-organ dysfunction. She was transferred to the ICU, and the team wasn't sure she could survive. CRS is the result of large numbers of CAR-T cells simultaneously activating and releasing cytokines: large amounts of CAR-T cells simultaneously activated in a short time, secreting TNF-α, IFN-γ, IL-6, and other cytokines reaching dangerous levels in blood, inducing systemic inflammatory response.
Just when the team was nearly despairing, June noticed an anomaly in Emily's blood test data: interleukin-6 (IL-6) levels were thousands of times normal values. He recalled tocilizumab — a drug used to treat rheumatoid arthritis, a monoclonal antibody antagonist of the IL-6 receptor that could block IL-6 signals and suppress cytokine storms. Without precedent, he decided to use tocilizumab. About twenty-four hours after administration, Emily's condition began rapidly improving. Fever broke, blood pressure recovered, consciousness cleared. Test results showed: leukemia cells in her body had completely disappeared. In 2022, Emily's complete remission reached ten years. She is not only alive but attending university in good health. Her case rewrote CAR-T history in two dimensions: first, proving CD19 CAR-T can achieve complete remission in childhood ALL; second, June's use of tocilizumab to control CRS provided a clinical template for managing CAR-T therapy's most dangerous side effect — this method was later written into standard procedures at all global CAR-T treatment centers.
|
CAR-T's breakthrough wasn't in any single 'discovery moment' — it was accumulation of countless failures and adjustments over thirty years: concept, failure, add co-stimulatory domain, fail again, find target, deal with cytokine storm. Every problem solved pushed this therapy one step forward. |
5. CAR-T today: achievements and limitations
In 2017, Kymriah received FDA approval for relapsed or refractory B-ALL in patients twenty-five and under. In 2018, Yescarta was approved for large B-cell lymphoma. Subsequently, multiple CAR-T products were approved covering multiple myeloma (BCMA target), follicular lymphoma, and mantle cell lymphoma. In relapsed/refractory B-ALL, Kymriah's complete remission rate reaches eighty-one percent, with many patients having previously exhausted all treatment options. But CAR-T's limitations are equally real, especially prominent in solid tumors. Blood cancer successes were achievable partly because of CD19 targets' ideal characteristics and the blood environment's relative friendliness to CAR-T. Solid tumors (lung cancer, colorectal cancer, pancreatic cancer, etc.) face more challenges: tumor microenvironments are full of immunosuppressive signals (TGF-β, IL-10, regulatory T cells), CAR-T cells struggle to penetrate solid tumors, and even when penetrating tend to rapidly exhaust. Manufacturing complexity and high price are another real barrier. Each patient's CAR-T is individually customized — from patient blood cell extraction, through viral vector transfection, in vitro activation and expansion, to final infusion — typically taking two to four weeks; manufacturing cost in the United States can reach $370,000–470,000. Next-generation CAR-T technology is trying to solve these problems: 'off-the-shelf' allogeneic CAR-T using healthy donor T cells to greatly reduce costs; CAR-NK provides an allogeneic option not needing HLA matching; 'armored' CAR-T helps T cells survive in solid tumor suppressive environments through additional genetic engineering.
Frequently Asked Questions